Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Our goal is to have at least one antibody to every human expressed gene in human genome.
In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. There products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors around the world.
Starting from Year 2009 to 2013, in Phase II of the business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentation for rare cell isolation. In Phase III, we focus on in vitro diagnostics development concentrating on non-invasive, liquid biopsies of circulating tumor cells, ctDNA, and exosomes for precision medicine. Now in Phase IV (Year 2017 and later), we have focused on drug development specializing on immunotherapy. The value-added business has set the path of company's future growth and provided opportunity for Abnova to contribute to the biotech industry at large.
We welcome researchers, biotech, and pharmaceutical companies to work with us and succeed together!
AltaBioscience is recognised worldwide as a leading manufacturing and analysis laboratory providing synthesis of DNA and peptides and analysis of proteins and other biochemical molecules, to researchers in academia, pharmaceuticals and the food industry.
Certified to ISO/IEC 17025:2005 for amino acid analysis, protein sequencing and steroid analysis. ISO 9001:2008 for the laboratory as a whole, AltaBioscience is committed to supplying high-quality products and analytical services at competitive prices.
AutekBio, Inc. (www.autekbio.com) is a biopharmaceutical contract development and manufacturing company (CDMO) specializing in the production of therapeutic proteins and antibodies from mammalian cell culture. AutekBio has developed proprietary, integrated technology platforms to provide one-stop total solution “from DNA to NDA” for biopharmaceutical companies. Headquartered in the US, with manufacturing facility conveniently located in the Free Trade Zone of Beijing, AutekBio is uniquely positioned to be your trusted partner to open new frontier in the world of quality therapeutic biologics.
Our Mission: A Premier China Based Biologic CMO for the World
• No internal product development – Service Only
• No drug discovery program – CMO Only
• Serve our partners’ manufacturing needs - “from DNA to NDA”
• Open new frontiers in manufacturing quality therapeutic biologics
• Deliver affordable biologics to the needed
• Gateway to Chinese market
Batavia Biosciences is a science-based CDMO that offers personalized services that fully support all the stages of biopharmaceutical development, from cloning to GMP manufacture and release of clinical material for phase I/II studies. We are not your standard CDMO - our customers regularly refer to us as their product development partner and thought partner.
We focus on the early stages of product development with services ranging from DNA cloning, mammalian cell line generation, upstream process development, purification development, product characterization to clinical manufacturing. Headquartered in Leiden, The Netherlands, Batavia Biosciences is privileged to have strong strategic partners in both the EU and US.
Batavia Biosciences aims to significantly contribute to ease human suffering from infectious disease and cancer.
Bharat Biotech International Limited is a multidimensional biotechnology company specializing in product-oriented research and development leading to the manufacture of vaccines and bio-therapeutics in Hyderabad, India. Bharat Biotech was established in the year 1996 by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella.
Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. We seek to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets.
Our significant R&D investments have yielded several breakthroughs including the world’s 1st Eco-friendly recombinant Hepatitis-B vaccine (free of cesium chloride and Thiomersal).Rotavirus vaccine from a naturally attenuated strain,Typhoid Conjugate vaccine.
Transparency and openness are central to our DNA. An uncompromising commitment to integrity differentiates us. Our clinical trials are known for their rigor and breadth. We also adopt the most comprehensive data integrity procedures to ensure that we capture, store and report data accurately. We are committed to provide affordable and innovative vaccines for healthier lives.
Bharat Biotech launched India’s first recombinant Epidermal Growth Factor (REGEN-D®) to combat diabetic foot ulcers, burns.
Typbar TCV® is the world’s first clinically proven conjugate Typhoid vaccine and received WHO-Prequalification in January 2018.
ROTAVAC® was India’s first and largest efficacy clinical trial on vaccines and Rotavac® received WHO-Prequalification in January 2018.
Bharat Biotech Launches ROTAVAC 5D®- Lowest dose volume
Rotavirus vaccine - ROTAVAC in the world launched in December 2019.
COVAXIN, India's indigenous COVID-19 vaccine by Bharat Biotech.